{
    "nctId": "NCT06106529",
    "briefTitle": "REDucing Hot FLASHes in Women Using Endocrine Therapy.",
    "officialTitle": "A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Hot Flash Due to Medication",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 260,
    "primaryOutcomeMeasure": "Number and severity of hot flashes",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre-, peri- or postmenopausal women of 18 years or above;\n* Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;\n* Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.\n\nExclusion Criteria:\n\n* Pregnant;\n* Breast feeding;\n* Patients who receive chemotherapy or immunotherapy/HER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;\n* Palliative setting;\n* Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;\n* Creatinine clearance \\< 30 ml/min;\n* Liver cirrhosis;\n* Use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry;\n* Use of oxybutynin before study entry;\n* Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}